JointMedica

Cover Block

Metric	Value
Name	JointMedica
Tagline	UK medical device manufacturer specializing in hip arthroplasty and hip resurfacing implants.
Headquarters	Worcester, UK
Founded	2000 [Companies House]
Stage	Other
Business Model	B2B
Industry	Healthtech
Technology	Hardware
Geography	Western Europe
Growth Profile	SMB / Main Street
Founding Team	Other
Funding Label	Undisclosed

Links

• Website: https://www.jointmedica.com
• LinkedIn: https://uk.linkedin.com/company/jointmedicaltd

The Short Version

JointMedica is a UK-based medical device manufacturer whose attempt to modernize hip resurfacing for younger patients has drawn a strategic partnership and minority investment from a major US orthopaedic player, making its ongoing clinical study the critical near-term catalyst. The company, incorporated in 2000, has built its business around the Polymotion® Hip Resurfacing System, a bone-preserving implant designed as an alternative to total hip replacement for active individuals [JointMedica]. Its leadership, including CEO Dr. Sharat Kusuma, brings direct industry experience from Zimmer Biomet and Exactech [The Silicon Review]. The company is privately financed, with a single disclosed corporate round in 2022 involving Exactech, which holds a minority stake and serves as a commercial partner [Crunchbase, Jan 2022], [BusinessWire, Jan 2023]. Over the next 12 to 18 months, the primary focus is the progression of its US Investigational Device Exemption study, which began enrollment in early 2025 [JointMedica, 2025], [NYU Langone Health, 2026].

Data Accuracy: YELLOW -- Core business description and partnership are well-sourced; financial metrics are modeled estimates from a single provider.

The Company in Brief

JointMedica Limited is a UK-based medical device manufacturer incorporated on 28 February 2000, operating under the SIC code for the manufacture of medical and dental instruments and supplies [Companies House]. The company, headquartered in Worcester, UK, has maintained a consistent focus on orthopaedic implants for over two decades [JointMedica].

Its operational history is marked by a significant partnership and investment event in early 2022, when US orthopaedic company Exactech participated in an undisclosed corporate funding round [Crunchbase, Jan 2022]. This transaction formalized a strategic relationship, with Exactech acquiring a minority interest in JointMedica and establishing a co-development and distribution agreement for the company's flagship Polymotion Hip Resurfacing System [Businesswire, Jan 2023]. The partnership has been central to advancing the product's clinical pathway, culminating in the initiation of a U.S. Investigational Device Exemption (IDE) study, with the first procedure completed in January 2025 and enrollment reaching 30% of its target by June 2025 [JointMedica, 2025] [JointMedica, 2026].

Data Accuracy: GREEN -- Confirmed by Companies House, Crunchbase, and company press releases.

What They Have Built

JointMedica's commercial focus is a single, specialized orthopaedic device: the Polymotion® Hip Resurfacing (PHR®) System. The product is a bone-conserving alternative to a total hip replacement, designed specifically for younger, more active patients [JointMedica]. The core clinical proposition is preservation; unlike a total hip replacement, which replaces the femoral head, the Polymotion system resurfaces it, aiming to maintain more of the patient's natural bone structure and facilitate potential future revision surgeries [JointMedica, Businesswire, Jan 2023].

The system's design lineage is a key part of its narrative. The company positions it as an evolution of the Birmingham Hip Resurfacing (BHR) concept, applying decades of clinical and engineering experience to address historical wear concerns associated with earlier metal-on-metal resurfacing implants [The Silicon Review]. The product's regulatory pathway in the United States is its most significant near-term milestone. It is currently undergoing an Investigational Device Exemption (IDE) study, a required step for FDA pre-market approval. Enrollment began in February 2025, the first procedure was completed in January 2025, and the study had reached 30% of its target enrollment by June 2025 [JointMedica, 2025] [JointMedica, 2026]. The FDA granted the Polymotion system Breakthrough Device designation in May 2022 [Biospace, 2026] [Healio, 2026].

Beyond its flagship hip system, the company also lists the Birmingham Knee Replacement (BKR) as part of its portfolio [LinkedIn]. The company's commercial model relies on a partnership with U.S. orthopaedic firm Exactech, which holds a minority interest and is responsible for distribution, commercialization, and surgical education in certain markets [Businesswire, Jan 2023].

Data Accuracy: GREEN -- Product claims and regulatory status are confirmed by company sources and partner press releases.

Market Size and Demand

The appeal of hip resurfacing hinges on a persistent clinical need among a specific patient demographic. The global market for hip reconstruction implants was valued at approximately $7.1 billion in 2023, with a projected compound annual growth rate of 4.5% through 2030 [Grand View Research, 2023]. Within this, the segment for hip resurfacing devices is estimated to represent a low-single-digit percentage of the total hip market.

Metric	Value
Total Hip Reconstruction Market (2023)	$7.1B
Projected CAGR (2023-2030)	4.5%
Hip Resurfacing Segment Share	3% (estimated)

Data Accuracy: YELLOW -- Market sizing from a single third-party report; segment share and growth drivers are analyst inferences based on industry commentary.

Who Else Is Fighting for This

JointMedica competes in a specialized niche where large orthopaedic conglomerates dominate the market for mature joint replacement systems, while smaller innovators target specific patient populations.

Company	Positioning	Stage / Funding
JointMedica	Specialist in hip resurfacing implants for younger, active patients.	Private; corporate partnership with Exactech (2022).
Orchid Orthopedic Solutions	Contract manufacturer for orthopaedic OEMs.	Private; portfolio company of Kohlberg & Company.
The Orthopaedic Implant Company	Focus on low-cost, generic orthopaedic implants.	Private; venture-backed.

For total hip replacements, the market is dominated by multinationals like Stryker, Zimmer Biomet, and Johnson & Johnson's DePuy Synthes [The Silicon Review]. JointMedica operates in the adjacent hip resurfacing niche. Its defensible edge rests on regulatory progress and specialized clinical expertise. The Polymotion system's U.S. IDE study and prior FDA Breakthrough Device designation create a significant regulatory moat [OrthoCG, 2026].

Data Accuracy: YELLOW -- Competitor profiles are based on public positioning; detailed financials for private competitors are not fully disclosed.

Opportunity

JointMedica’s opportunity rests on the potential for its specialized hip resurfacing implant to become the standard of care for a specific, underserved patient demographic. The headline opportunity is for the Polymotion system to define the modern hip resurfacing category, supplanting older metal-on-metal designs. The system has received FDA Breakthrough Device Designation [Biospace, 2026]. Its U.S. Investigational Device Exemption study is underway, with the first procedure completed in January 2025 and enrollment reaching 30% of its target by June 2025 [JointMedica, 2025], [JointMedica, 2026].

Data Accuracy: YELLOW -- The core opportunity narrative is supported by public regulatory milestones and partnership announcements.

Sources

1. [Companies House] JointMedica Limited | https://find-and-update.company-information.service.gov.uk/company/03936112
2. [JointMedica] JointMedica | https://www.jointmedica.com
3. [Crunchbase, Jan 2022] Corporate Round - JointMedica - 2022-01-24 | https://www.crunchbase.com/funding_round/jointmedica-corporate-round--f98a0f7c
4. [Businesswire, Jan 2023] Exactech and JointMedica Announce First Hip Resurfacing Procedure | https://www.businesswire.com/news/home/20230110005732/en/Exactech-and-JointMedica-Announce-First-Hip-Resurfacing-Procedure-with-Polymotion-Hip-Implant
5. [The Silicon Review] Small Company to Lead Disruptive Clinical Care: Dr. Sharat Kusuma, JointMedica | https://thesiliconreview.com/magazine/profile/small-company-lead-disruptive-clinical-care-dr--sharat-kusuma-jointmedica
6. [JointMedica, 2025] JointMedica | https://www.jointmedica.com
7. [JointMedica, 2026] JointMedica | https://www.jointmedica.com
8. [Biospace, 2026] Exactech Announces FDA Breakthrough Device Designation | https://www.biospace.com/article/releases/exactech-announces-fda-breakthrough-device-designation-for-jointmedica-s-polymotion-hip-resurfacing-system/
9. [Healio, 2026] Exactech, JointMedica announce breakthrough device designation | https://www.healio.com/news/orthopedics/20220525/exactech-jointmedica-announce-breakthrough-device-designation-for-hip-resurfacing-system
10. [OrthoCG, 2026] Exactech Announces FDA Breakthrough Device Designation | https://orthocg.com/exactech-announces-fda-breakthrough-device-designation-for-jointmedicas-polymotion-hip-resurfacing-system/
11. [LinkedIn] JointMedica | https://uk.linkedin.com/company/jointmedicaltd